Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

The U.S. Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups, as an ...

Kepler Capital analyst David Evans maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) on October 30 and set a price ...

Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products. Read More on GB:GSK: GSK NewsMORE Related Stocks Indices ...

The big pharma company GlaxoSmithKline will inject up to $800 million into its manufacturing site in Marietta, Pennsylvania, ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to the British drugmaker’s pipeline of potential treatments for lupus.

Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...

The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn ... reflecting strong performance of new products and the investment we've put ...

Furthermore, GSK is well known for providing its brand products with a price in Egypt that can be a fraction of its regular price in the region. Of the top 20 multinational corporations working in ...

(Reuters) -GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third quarter, ...

THE ARM FOR THE LANCASTER COUNTY ECONOMY. THIS IS FOR GSK, THE LARGEST INVESTMENT IN MANUFACTURING WE’VE EVER DONE IN THE UNITED STATES. THE $800 MILLION WILL BE USED TO EXPAND GSK’S MARIETTA ...